RDY Stock — Dr. Reddy's Laboratories Ltd: Cash, EV, Pipeline

Share price

$12.19

Market cap

$10,174.5M

Cash

$164.0M

Enterprise value

$10,101.4M

Balance sheet

Cash	$164.0M
Debt	$90.9M
Net cash	$73.1M
Enterprise value	$10,101.4M
Basic shares	835.0M shares
Fully diluted shares	837.5M shares
Fully diluted market cap	$10,209.5M
Cash per share	$0.20

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading RDY daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 9 - Mar 23	DRL_AB	Phase 1	Healthy Volunteers	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Biosimilar rituximab

Approved · Active Modality: biosimilar antibody

Aliases DRL_RI

Target CD20

Indications

Rheumatoid arthritis (Approved)
Non-Hodgkin's lymphoma (Approved)
Chronic lymphocytic leukemia (Approved)
Pemphigus vulgaris (Approved)
Granulomatosis with polyangiitis / microscopic polyangiitis (Approved)

Status note Approved in Canada (Feb 2026), EU (Sep 2024), UK (2024), Switzerland (Jan 2026). U.S. BLA under active FDA review (CRL Nov 2024; responses Apr 2025/Feb 2026).

Biosimilar abatacept (IV)

Stage not disclosed · Active Modality: biosimilar antibody

Indications

not disclosed (Stage not disclosed)

Status note BLA pending approval with U.S. FDA (as of Mar 31, 2026).

Biosimilar denosumab

Approved · Active Modality: biosimilar antibody

Target RANK ligand

Indications

Osteoporosis (Approved)
Prevention of skeletal-related events in multiple myeloma / bone metastases (Approved)

Catalysts

— 2026

Status note EMA approved (Nov 2025), UK approved (Dec 2025). FDA issued CRL Dec 2025; resubmission targeted 2026.

Per-asset detail extracted from the 20-F filed 2026-05-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	DRL_AB
Lead indication	Healthy Volunteers
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07744828	Phase 1	Not yet recruiting	Sponsor	Dr. Reddy's Laboratories Limited	—	Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Dr. Reddy's Laboratories Limited on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

RDY — Dr. Reddy's Laboratories Ltd

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials